Participants 426 478 3
 patients with relapsing-remitting multiple sclerosi
Participants 551 763 9
 76 centres in the Czech Republic, Germany, Hungary, India, Poland, Russia, Ukraine, Turkey, and the UK between Feb 15, 2008, and May 14, 2010. Patients aged 18-55 years with relapsing-remitting multiple sclerosi
Participants 1293 1391 3
 204 patients were assigned to receive placebo, 208 to daclizumab HYP 150 mg, and 209 to daclizuma
